The Paris Court of Appeals has handed down its judgment against Servier in the case involving its weight-loss therapy mediator, finding the company guilty of fraud and ordering it to pay €431 million ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported positive results for lead drug Tibsovo that could expand the use of the drug in acute ...

Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced ...

French biopharma Servier has bought up Danish cancer biotech Symphogen as it looks to bolster its immuno-oncology pipeline. The deal, financial terms of which have not been made public, unusually, ...

PARIS (Reuters) - Jacques Servier, founder and president of France's second-largest drugmaker, has died before his trial over Mediator, a weight-loss pill at the centre of the country's biggest public ...

A Servier Pharmaceuticals drug acquired as part of a $1.8 billion deal has won an additional FDA approval as a treatment for a rare type of blood cancer carrying a specific mutation. The regulatory ...

International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered ...

U.S. drugmaker Pfizer and France's Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers. The so-called CAR T cell technology ...